Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Biotech Competitive Intelligence’

The 2014 European Society for Medical Oncology (ESMO) Congress starts this weekend in Madrid, and it finally feels like it is starting to take off with the release today at lunch-time in Europe of the oral abstracts (with the exception of late breakers) to be presented at the meeting.

This blog post is a preview of some of the oral abstracts that caught my attention in a quick preview this afternoon while in Paris en-route to Madrid.

Air France Concorde CDGFollowing its success at ASCO (one subscriber told us it helped him schedule which sessions to attend, another that it enabled him to question his team on what was really hot at the meeting), we’ll be writing a daily blog on Saturday, Sunday and Monday from ESMO.

It’s going to be a live blog in the sense that we plan to regularly update it during the day, and it will include details of which sessions we are in and our initial impressions of data that catches our interest.

More in-depth posts will follow later.

Back to the oral abstracts, subscribers can login below to read about some of the abstracts that have caught my attention. If you are not yet a subscriber, we do hope you will consider joining what is an exclusive club.

If you can only afford to sign up for a quarter you’re in for a treat as in addition to ESMO we will be covering in person two other major medical meetings this fall, including ASH in San Francisco, and (for now) you still get to read all our previous coverage!!

PS: we’ve not mentioned the companies and products covered in this introduction, as that would make it too easy for non-subscribers, or those in the media who constantly ask us at conferences for story ideas… we all need an edge 🙂

Marching Band Changing Guard LondonToday marks a year since we put up a paywall on Biotech Strategy Blog. While we were sorry to have to restrict access in this way, our decision reflects what is happening in the wider digital media arena, it’s simply not possible to go to conferences and generate quality content for free!

It was Warren Buffett who said, “Price is what you pay, value is what you get” and that’s how we feel about charging for access to Premium Content on the blog.

When we put a paywall up on the blog last September, many thought it would not last. All those who bet on its early demise are still waiting 😉

What the paywall has done is create an exclusive club that have access to our insights and analysis. Other traditional media organizations are now following suit, by charging a membership fee for premium access.

There is a wealth of free data on the Internet, and lots of media folk do a good job of sharing or curating this, but raw data is not intelligence, nor do they tell you anything about context or meaning. Insights also require knowledge, expertise and thought to generate.

Journalism and digital media are going through a revolution as those who create original content seek to get paid for it. We are part of that vanguard. So this post is a big thank you for all our subscribers from around the world who have supported our initiative.

Our thanks also to Tinypass, who as our technology partner, creates the paywall and administers the payment processing system. We could not have achieved the success we have had without them.

Year in Review:

Looking back at this year, we’ve covered remotely or on site 10 conferences or scientific meetings:

  • ECCO 2013 (Amsterdam)
  • AACR-EORTC-NCI Molecular Targets (Boston)
  • World Lung (Sydney)
  • ASH 2013 (New Orleans)
  • SABCS (San Antonio)
  • JPM 2014 (San Francisco)
  • ASCO GI (San Franciscso)
  • ASCO GU (San Francisco)
  • Miami Breast
  • AACR 2014 (San Diego)
  • AUA 2014 (Orlando)
  • ASCO 2014 (Chicago)

Funding from our subscribers enabled us to attend most of these meetings in person. In addition we’ve followed interesting new stories e.g. by going to Paris to interview the senior management of Cellectis about their CAR-T cell therapy.

By my calculation we’ve written approximately 120 premium content posts of the past year, so the cost per post at the current annual rate is about $10. Those who signed up for special offers got them for even less.

So thanks to everyone who has supported us over the past year, we greatly appreciate you being part of the journey with us. We look forward to welcoming new subscribers over the coming year.

For a limited time only (until end of October) we are offering a special anniversary offer where you can lock in your rate for 2 years. Just click on any post and scroll down to sign up in the box under the post.

Check it out!


error: Content is protected !!